The global Periodontal Therapeutics Market is highly consolidated in nature on account of a few players holding most of the share in the market. Some of the key players in the market are Den-Mat Holdings, Valeant Pharmaceuticals international, Inc., 3M, Galderma S.A., and LLC Dexcel Pharma. In 2015, 3M, Valeant Pharmaceuticals Int. Inc., and Den-Mat Holdings emerged as the top three players in the market and together they accounted for a mammoth share of 77.7%.
A key trend noticed in the global market for periodontal therapeutics is the investment into research and development of more effective therapies by prominent participants. This, coupled with the focus on strategic mergers and acquisitions and partnerships by players seeking to expand their outreach, is serving to heat up competition in the market.
A report by Transparency Market Research predicts the global periodontal therapeutics market to register a CAGR of 8.7% during the period between 2016 and 2024 to attain a value of US$537.2 mn by 2024.
Request to View Sample of Report –
Based on the type of products, the global market for periodontal therapeutics can be divided into systemic antibiotics and local antibiotics. Among the two, the systemic antibiotics segment dominated the market in 2016 with a lion’s share for more than 94%. In the years ahead, the segment is slated to continue to rake in maximum revenue, although reducing its share slightly because of its affordability and availability.
Geographically, the key segments of the global market for periodontal therapeutics are North America, Asia Pacific, Europe, and the Rest of the World. North America, of them, led the market in 2015 with a dominant share of more than 40.0%. This is primarily on account of the rising occurrence of periodontal diseases, product innovation, helpful reimbursement policies, and a growing pool of elderly. As per the Center for Disease Control and Prevention, 47.2% of adults 30 years and above is afflicted with some type of periodontal disease. This, along with increasing awareness about the ailment is expected to drive the market.